Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
Aspirin chemical structure
|ATC code |
A01AD05 ., .
|Molecular weight||180.160 g/mol|
|Bioavailability||rapid & complete|
|Elimination half-life||300–650 mg dose: 3.1–3.2hrs|
1 g dose: 5 hours
2 g dose: 9 hours
|Routes of administration||oral|
Aspirin, or acetylsalicylic acid (IPA: [əˈsɛtlˌsæləˈsɪlɪk ˈæsɪd]), (acetosal) is a drug in the family of salicylates, often used as an analgesic (to relieve minor aches and pains), antipyretic (to reduce fever), and as an anti-inflammatory. It also has an antiplatelet ("blood-thinning") effect and is used in long-term, low doses to prevent heart attacks and thrombus formation in hypercoaguable states (e.g.in cancer).
Low-dose, long-term aspirin use irreversibly blocks the formation of thromboxane A2 in platelets, producing an inhibitory effect on platelet aggregation. This anticoagulant property makes it useful for reducing the incidence of heart attacks. Aspirin produced for this purpose often comes in 75 or 81 mg, dispersible tablets and is sometimes called "junior aspirin" or "baby aspirin." High doses of aspirin are also given immediately after an acute heart attack. These doses may also inhibit the synthesis of prothrombin and may, therefore, produce a second and different anticoagulant effect, but this is not well understood.
Its primary, undesirable side-effects, especially in higher doses, are gastrointestinal distress (including ulcers and stomach bleeding) and tinnitus. Another side-effect, due to its anticoagulant properties, is increased bleeding in menstruating women. Because there appears to be a correlation between aspirin and Reye's syndrome in children under the age of about 12, aspirin is no longer used to control flu-like symptoms or the symptoms of chickenpox in minors.
Aspirin was the first-discovered member of the class of drugs known as non-steroidal, anti-inflammatory drugs (NSAIDs), not all of which are salicylates, though they all have similar effects and a similar action mechanism.
Aspirin as genericized trademark
The brand name Aspirin was coined by the Bayer company of Germany. In some countries the name is used as a generic term for the drug rather than the manufacturer's trademark. In countries in which Aspirin remains a trademark, the initialism ASA (for acetylsalicylic acid) is used as a generic term.
The name "aspirin" is composed of a- (from the acetyl group) -spir- (from the plant genus Spiraea) and -in (a common ending for drugs at the time). It has also been stated that the name originated by another means. "As" referring to AcetylSalicylic and "pir" in reference to one of the scientists who was able to isolate it in crystalline form, Raffaele Piria. Finally, "in" because it was a common ending for drugs at the time.
On March 6, 1899, Bayer registered it as a trademark. However, the German company lost the right to use the trademark in many countries because the Allies seized and resold its foreign assets after World War I. The right to use "Aspirin" in the United States (along with all other Bayer trademarks) was purchased from the U.S. government by Sterling Drug in 1918. Even before the patent for the drug expired in 1917, Bayer had been unable to stop competitors from copying the formula and using the name elsewhere, so, with a flooded market, the public was unable to recognize "Aspirin" as coming from only one manufacturer. Sterling was subsequently unable to prevent "Aspirin" from being ruled a genericized trademark in a U.S. federal court in 1921. Sterling was ultimately acquired by Bayer in 1994, but this did not restore the U.S. trademark. Other countries (such as Canada and many countries in Europe) still consider "Aspirin" a protected trademark.
Hippocrates, a Greek physician, wrote in the 5th century BC about a bitter powder extracted from [willow bark that could ease aches and pains and reduce fevers. This remedy is also mentioned in texts from ancient Sumer, Lebanon, and Assyria. The Cherokee and other Native Americans used an infusion of the bark for fever and other medicinal purposes for centuries. The medicinal part of the plant is the inner bark and was used as a pain reliever for a variety of ailments. The Reverend Edward Stone, a vicar from Chipping Norton, Oxfordshire, England, noted in 1763 that the bark of the willow was effective in reducing a fever.
The active extract of the bark, called salicin, after the Latin name for the white willow (Salix alba), was isolated to its crystalline form in 1828 by Henri Leroux, a French pharmacist, and Raffaele Piria, an Italian chemist. Piria was able to convert the substance into a sugar and a second component, which on oxidation becomes [[salicylic acid
Salicylic acid was also isolated from the herb meadowsweet (Filipendula ulmaria, formerly classified as Spiraea ulmaria) by German researchers in 1839. While their extract was somewhat effective, it also caused digestive problems such as gastric irritation and bleeding and diarrhea, and even death when consumed in high doses.
A French chemist Charles Frederic Gerhardt was first to prepare acetylsalicylic acid (future aspirin) in 1853. In the course of his work on the synthesis and properties of various acid anhydrides, he mixed acetyl chloride with a sodium salt of salicylic acid (sodium salicylate). A vigorous reaction ensued, and the resulting melt soon solidified. Since no structural theory existed at that time Gerhardt called the compound he obtained "salicylic-acetic anhydride" (wasserfreie Salicylsäure-Essigsäure). When Gerhardt tried to dissolve the solid in a diluted solution of sodium carbonate it immediately decomposed to sodium salts of salicylic and acetic acids. This preparation of aspirin ("salicylic-acetic anhydride") was one of the many reactions Gerhardt conducted for his paper on anhydrides, and he did not pursue it further.
Six years later in 1859 von Gilm obtained analytically pure acetylsalicylic acid (he called it "acetylirte Salicylsäure") by a reaction of salicylic acid and acetyl chloride. In 1869 Schröder, Prinzhorn and Kraut (Prinzhorn is credited in the paper with conducting the experiments) repeated both Gerhardt's (from sodium salicylate) and von Gilm's (from salicylic acid) syntheses and concluded that both reactions gave the same compound--acetylsalicylic acid. They were first to assign to it the correct structure with the acetyl group connected to the phenolic oxygen.
In 1897 Felix Hoffmann a chemist at Friedrich Bayer & Co. obtained acetylsalicylic acid by a reaction of salicylic acid and acetic anhydride, that is essentially repeating the Gilm/Kraut procedure but substituting acetic anhydride for acetyl chloride. This synthesis served as the basis for Bayer claims to discovery of aspirin. According to a legend publicized by Bayer, Hoffmann made some of the formula and gave it to his father, who was suffering from the pain of arthritis and could not stand the side-effects of salicylic acid. Much later in 1949 another Bayer researcher Arthur Eichengrün asserted his own priority as a discoverer of aspirin (see below for the details of Hoffmann-Eichengrün controversy). This argument did much to obscure the real history of aspirin, whose origins is not the pharmaceutical industry but an earlier academic research. Despite the fact that pure aspirin was synthesized by von Gilm and by Kraut's group many years before Hoffmann (see above), Bayer continues to insist that "The active ingredient in Aspirin®, acetylsalicylic acid, was synthesized for the first time in a chemically pure and thus stable form in 1897 by a young chemist working for Bayer, Dr. Felix Hoffmann."
However, German patent office refused to grant Bayer patent for acetylsalicylic acid on the grounds that neither the product nor the process of preparation were novel. In 1905 Bayer sued Chemische Fabrik von Heyden in Britain for infringing the British patent on aspirin granted to it in 1900. Hayden claimed that existing prior art, in particular Kraut's work invalidated Bayer's patent. Bayer advanced the argument that they were first to prepare pure form of aspirin. Judge agreed with Hayden and invalidated Bayer patent. Similar struggle took place in the Circuit court in Chicago; however, in the US the Bayer's patent was upheld in 1909. This created a situation when aspirin in the US was three times more expensive than in Canada and ten times more expensive than in Europe, and resulted in rampant smuggling of aspirin, which Bayer unsuccessfully tried to contain. 
Bayer began marketing aspirin in July 1899. It was marketed alongside another of Hoffmann's products, an acetylated derivative of morphine called 'Heroin' that he invented 11 days after aspirin[How to reference and link to summary or text]. Heroin was initially the more successful of the two painkillers and it was common belief that it was healthier than aspirin. But, as heroin's shortcoming of addictiveness became more obvious, aspirin stepped to the forefront. Aspirin was originally sold as a powder (still the preferred form in many European countries) and was an instant success; in 1914, Bayer introduced aspirin tablets.
Several claims to invention of acetylsalicylic acid have arisen. Acetylsalicylic acid was already being manufactured by the Chemische Fabrik von Heyden Company in 1897, although without a brand name[How to reference and link to summary or text]. A new pretender to the title of aspirin discoverer appeared in 1949. Arthur Eichengrün who was 81 "claimed that he had instructed Hoffmann to synthesise acetylsalicylic acid and that the latter had done so without knowing the purpose of the work". In 2000, Walter Sneader of University of Strathclyde in Glasgow reexamined the case and concluded that "Arthur Eichengrün was telling the truth when he wrote that acetylsalicylic acid was synthesised under his direction and that the drug would not have been introduced in 1899 without his intervention". Subsequently, in his polemic with Sneader, Axel Helmstaedter, General Secretary of International Society for the History of Pharmacy, noted that Sneader did not credit several earlier publications which discussed the Hoffmann-Eichengrün controversy in detail, with most historians doubting Eichengrün's account. Bayer countered to Sneader in a press-release that according to the records, Hoffmann and Eichengrün held equal positions, and Eichengrün was not Hoffmann's supervisor. Hoffmann was named on the US Patent as the inventor, which Sneader did not mention. Eichengrün who left Bayer in 1908 had multiple opportunities to claim the priority and had never before 1949 done it; neither he claimed or received any percentage of the profit from aspirin sales.
It was not until the 1970s that the mechanism of action of aspirin and similar drugs called NSAIDs was elucidated (see below).
Synthesis of aspirin
The synthesis of aspirin is classified as an esterification reaction, where the alcohol group from the salicylic acid reacts with an acid (acetyl anhydride) to form an ester. Aspirin is commercially synthesized using a two-step process. First, phenol (generally extracted from coal tar) is treated with a sodium base which generates sodium phenoxide, which is then reacted with carbon dioxide under high temperature and pressure to yield salicylate, which is acidified, yielding salicylic acid. This process is known as the Kolbe-Schmitt reaction.
Salicylic acid is then acetylated using acetic anhydride, yielding aspirin and acetic acid as a byproduct. It is a common experiment performed in undergraduate organic chemistry practicals, and generally tends to produce low yields due to the relative difficulty of its extraction from an aqueous state. The trick to getting the reaction to work is to acidify with phosphoric acid and heat the reagents under reflux with a boiling water bath for between 40 to 60 minutes.
The original synthesis of aspirin from salicylic acid involved acetylation with acetyl chloride. Unfortunately, the byproduct from this is hydrochloric acid, which is corrosive and environmentally hazardous. As described above, it was then later found that acetic anhydride was a better acylating agent, with the byproduct acetic acid formed, which does not have the unwanted properties of hydrochloric acid and can also be recycled. The salicylic acid/acetic anhydride method is commonly employed in undergraduate teaching labs.
Formulations containing high concentrations of aspirin often smell like vinegar. This is because aspirin can undergo autocatalytic degradation to salicylic acid in moist conditions, yielding salicylic acid and acetic acid.
Mechanism of action
In 1971, the British pharmacologist, John Robert Vane, who was then employed by the Royal College of Surgeons in London, showed that aspirin had suppressed the production of prostaglandins and thromboxanes. For this piece of research he was awarded both a Nobel Prize in Physiology or Medicine in 1982 and a knighthood.
Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its non-competitive and irreversible inhibition of the cyclooxygenase (COX) enzyme. Cyclooxygenase is required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the COX enzyme. This makes aspirin different from other NSAIDs (such as diclofenac and ibuprofen), which are reversible inhibitors.
Prostaglandins are local hormones (paracrine) produced in the body and have diverse effects in the body, including but not limited to transmission of pain information to the brain, modulation of the hypothalamic thermostat, and inflammation. Thromboxanes are responsible for the aggregation of platelets that form blood clots. Heart attacks are primarily caused by blood clots, and their reduction with the introduction of small amounts of aspirin has been seen to be an effective medical intervention. The side-effect of this is that the ability of the blood in general to clot is reduced, and excessive bleeding may result from the use of aspirin.
There are at least two different types of cyclooxygenase: COX-1 and COX-2. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. Normally COX-2 produces prostanoids, most of which are pro-inflammatory. Aspirin-modified COX-2 produces lipoxins, most of which are anti-inflammatory. Newer NSAID drugs called COX-2 selective inhibitors have been developed that inhibit only COX-2, with the hope for reduction of gastrointestinal side-effects.
However, several of the new COX-2 selective inhibitors have been recently withdrawn, after evidence emerged that COX-2 inhibitors increase the risk of heart attack. It is proposed that endothelial cells lining the microvasculature in the body express COX-2, and, by selectively inhibiting COX-2, prostaglandins (specifically PGI2; prostacyclin) are downregulated with respect to thromboxane levels, as COX-1 in platelets is unaffected. Thus, the protective anti-coagulative effect of PGI2 is decreased, increasing the risk of thrombus and associated heart attacks and other circulatory problems. Since platelets have no DNA, they are unable to synthesize new COX once aspirin has irreversibly inhibited the enzyme, an important difference with reversible inhibitors.
Furthermore, aspirin has 2 additional modes of actions, contributing to its strong analgesic, antipyretic and anti-inflammatory properties:
- It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons. In short, aspirin buffers and transports the protons. (Note: This effect in high doses of aspirin actually causes fever due to the heat released from the electron transport chain, instead of its normal antipyretic action.)
- It induces the formation of NO-radicals in the body that enable the white blood cells (leukocytes) to fight infections more effectively. This has been found recently by Dr. Derek W. Gilroy, winning Bayer's International Aspirin Award 2005.
More recent data suggest that salicylic acid and its derivatives will modulate NFκB signaling.[How to reference and link to summary or text] NFκB is a transcription factor complex that plays a central role in many biological processes, including inflammation.
Aspirin, as with many older drugs, has proven to be useful in many conditions. Despite its well-known toxicity it is widely used, since physicians are familiar with its properties. Indications for its use include:
- Pain (especially useful for some forms of arthritis, osteoid osteoma, and chronic pain)
- Rheumatic fever (drug of choice)
- Kawasaki disease (along with IVIG)
- Coronary artery disease
- Acute myocardial infarction
In addition, aspirin is recommended (low dose, 75-81 mg daily) for the prevention of:
- Myocardial infarction — in patients with either documented coronary artery disease or at elevated risk of cardiovascular disease. Women may possibly benefit less from aspirin than men.
- Stroke — as secondary prevention (i.e. to prevent recurrence)
For adults doses of 300 to 1000 mg are generally taken four times a day for fever or arthritis, with a maximum dose of 8000 mg a day. The correct dose of aspirin depends on the disease process that is being treated. For instance, for the treatment of rheumatic fever, doses near the maximal daily dose have been used historically. For the prevention of myocardial infarction in someone with documented or suspected coronary artery disease, doses as low as 75 mg daily (or possibly even lower) are sufficient.
For those under 12 years of age, the dose previously varied with the age, but aspirin is no longer routinely used in children due to the association with Reye's syndrome; paracetamol or other NSAIDs, such as Ibuprofen, are now being used instead. Kawasaki disease remains one of the few indications for aspirin use in children with aspirin initially started at 7.5-12.5 mg/kg body weight taken four times a day for up to two weeks and then continued at 5 mg/kg once daily for a further six to eight weeks.
Dangers of low-dose aspirin
A recent review states: "....low-dose aspirin increases the risk of major bleeding 2-fold compared with placebo. However, the annual incidence of major bleeding due to low-dose aspirin is modest—only 1.3 patients per thousand higher than what is observed with placebo treatment. Treatment of approximately 800 patients with low-dose aspirin annually for cardiovascular prophylaxis will result in only 1 additional major bleeding episode." Further, "...the cost to prevent one major GI bleeding episode from aspirin in 1 year by substituting clopidogrel therapy would be $1,216,180..."
Contraindications and warnings
- Aspirin should be avoided by those known to be allergic to ibuprofen or naproxen.
- Caution should be exercised in those with asthma or NSAID-precipitated bronchospasm.
- It is generally recommended that one seek medical help if symptoms do not improve after a few days of therapy.
- Caution should be taken in patients with kidney disease, peptic ulcers, mild diabetes, gout or gastritis; manufacturers recommend talking to one's doctor before using this medicine.
- Taking aspirin with alcohol increases the chance of gastrointestinal hemorrhage (stomach bleeding).
- Children, including teenagers, are discouraged from using aspirin in cold or flu symptoms as this has been linked with Reye's syndrome.
- Patients with hemophilia or other bleeding tendencies should not take salicylates.
- Some sources recommend that patients with hyperthyroidism avoid aspirin because it elevates T4 levels. 
- Gastrointestinal complaints (stomach upset, dyspepsia, heartburn, small blood loss). To help avoid these problems, it is recommended that aspirin be taken at or after meals. Undetected blood loss may lead to hypochromic anemia. The Gastrointestinal complications that may result from a dose of Aspirin are due to Aspirin inhibitory action on Cyclo-oxygenase 1 and 2.
- Severe gastrointestinal complaints (gross bleeding and/or ulceration), requiring discontinuation and immediate treatment. Patients receiving high doses and/or long-term treatment should receive gastric protection with high-dosed antacids, ranitidine or omeprazole.
- Frequently, central effects (dizziness, tinnitus, hearing loss, vertigo, centrally mediated vision disturbances, and headaches). The higher the daily dose is, the more likely it is that central nervous system side-effects will occur.
- Sweating, seen with high doses, independent from antipyretic action
- Long-term treatment with high doses (arthritis and rheumatic fever): often increased liver enzymes without symptoms, rarely reversible liver damage. The potentially fatal Reye's syndrome may occur, if given to pediatric patients with fever and other signs of infections. The syndrome is due to fatty degeneration of liver cells. Up to 30 percent of those afflicted will eventually die. Prompt hospital treatment may be life-saving.
- Chronic nephritis with long-term use, usually if used in combination with certain other painkillers. This condition may lead to chronic renal failure.
- Prolonged and more severe bleeding after operations and post-traumatic for up to 10 days after the last aspirin dose. If one wishes to counteract the bleeding tendency, fresh thrombocyte concentrate will usually work.
- Skin reactions, angioedema, and bronchospasm have all been seen infrequently.
- Patients that have the genetic disease known as Glucose-6-Phosphate Dehydrogenase deficiency (G6PD) should avoid this drug as it is known to cause hemolytic anemia in large doses depending on the severity of the disease.
Aspirin can interact with some other drugs. Some drugs, for example those used for diabetes, are bound by plasma protein in the blood supply and are therefore not free to react with their targets. However, aspirin may displace them from plasma protein, leading to a drug overdose. Aspirin has this same effect on anticoagulants.
Aspirin overdose can be acute or chronic. In acute poisoning, a single large dose is taken; in chronic poisoning, supratherapeutic doses are taken over a period of time. Acute overdose has a mortality rate of 2%. Chronic overdose is more commonly lethal with a mortality rate of 25%; chronic overdose may be especially severe in children.
Aspirin overdose has potentially serious consequences, sometimes leading to significant morbidity and mortality. Patients with mild intoxication frequently have nausea and vomiting, abdominal pain, lethargy, tinnitus, and dizziness. More significant symptoms occur in more severe poisonings and include hyperthermia, tachypnea, respiratory alkalosis, metabolic acidosis, hyperkalemia, hypoglycemia, hallucinations, confusion, seizure, cerebral edema, and coma. The most common cause of death following an aspirin overdose is cardiopulmonary arrest usually due to pulmonary edema.
The toxic dose of aspirin is generally considered greater than 150 mg per kg of body mass. Moderate toxicity occurs at doses up to 300 mg/kg, severe toxicity occurs between 300 to 500 mg/kg, and a potentially lethal dose is greater than 500 mg/kg. This is the equivalent of many dozens of the common 325 mg tablets, depending on body weight. Note that children cannot tolerate as much aspirin per unit body weight as adults can, even when aspirin is indicated. Label-directions should be followed carefully.
All overdose patients must be taken to a hospital immediately.
Initial treatment of an acute overdose includes gastric decontamination of the patient. This is achieved by administering activated charcoal which adsorbs the aspirin in the gastrointestinal tract. Stomach pumps are no longer routinely used in the treatment of poisonings but are sometimes considered if the patient has ingested a potentially lethal amount up to 1 hour previously. Repeated doses of charcoal have been proposed to be beneficial in aspirin overdose. A study performed found that repeat dose charcoal might not be of significant value. However, most toxicologists will administer additional charcoal if serum salicylate levels are increasing.
Patients are monitored until their peak salicylate blood level has been determined. Blood levels are usually performed 4 hours after ingestion and then every 2 hours after that to determine the maximum level. Maximum levels can be used as a guide to toxic effects expected.
There is no antidote to salicylate poisoning. Frequent blood work is performed to check metabolic, salicylate, and blood sugar levels; arterial blood gas assessments are performed to test for respiratory alkalosis and metabolic acidosis. Patients are monitored and often treated according to their individual symptoms, patients may be given intravenous potassium chloride to counteract hypokalemia, glucose to restore blood sugar levels, benzodiazepines for any seizure activity, fluids for dehydration, and importantly sodium bicarbonate to restore the blood's sensitive pH balance. Sodium bicarbonate also has the effect of increasing the pH of urine, which in turn increases the elimination of salicylate. Additionally, hemodialysis can be implemented to enhance the removal of salicylate from the blood. Hemodialysis is usually used in severely poisoned patients; for example, patients with significantly high salicylate blood levels, significant neurotoxicity (agitation, coma, convulsions), renal failure, pulmonary edema, or cardiovascular instability are hemodialyzed. Hemodialysis also has the advantage of restoring electrolyte and acid-base abnormalities; hemodialysis is often life-saving in severely ill patients.
In the later part of the 20th century the number of salicylate poisonings has declined mainly due to the popularity of other over-the-counter analgesics such as paracetamol. Fifty-two deaths involving single-ingredient aspirin were reported in the United States in the year 2000. However, in all but three cases, the reason for the ingestion of lethal doses was intentional, predominantly suicides.
Research into cancer prevention
The role that aspirin might have in reducing the rates of certain cancers has been the subject of many studies. However, given the side-effects of NSAIDs on increased gastrointestinal bleeding and rates of heart disease, there is no current medical recommendation to use these drugs for cancer reduction.
- Prostate - While there is some epidemiological information suggesting a correlation between the reduction of prostate cancer and aspirin use, two recent studies (a multicentric case-control study and epidemiological study) were inconclusive.
- Colon - A 2005 JAMA article states that aspirin may prevent carcinoma of the colon, when taken in at least twice-daily adult (325 mg) doses. It follows an earlier study, also using the Nurses' Health Study (NHS) women, which had similar conclusions but with a smaller testing population. The conclusion of the JAMA study was that both aspirin and other non-aspirin NSAIDs used over a long time (best results seen after at least a decade of regular use) reduce risk of colorectal cancer. The risk was reduced the most at doses higher than 14 tablets per week (full-strength aspirin twice a day). However, these doses can have a higher incidence of serious gastrointestinal bleeding, and reduced doses (even the low doses recommended for cardiovascular health (81 mg/day)) also seem to have an anti-cancer effect, albeit not as much as the higher doses. The results of these studies have been correlated with experimental studies in human volunteers and in rodents. At least four clinical trials show that small doses of aspirin reduce, modestly, intestinal polyps recurrence in patients with some history of adenomas.  Some twenty carcinogenesis studies in rats or mice also support that aspirin can prevent cancer, also reported in the Chemoprevention of Colorectal Cancer Database.
- Gall bladder - There is some evidence that aspirin may increase gall bladder motility and thus be effective in treating gall bladder disease.[How to reference and link to summary or text]
- Pancreatic - A study in 2004 showed that increases in dose and duration of aspirin may significantly increase the risk of pancreatic cancer in women (only women were in the study); however this did not seem to affect current, regular users.
- Upper GI tract - A study published in 2003 reported that people who had been taking aspirin regularly for 5 or more years seemed to have a two-thirds less risk of mouth, throat and esophageal cancer than non-users. This study was done on both cancer patients and other people in hospital for various reasons, and was done by comprehensive epidemiological questionnaires of life habits rather than empirical testing.
- Lung - A 20-year study published in 2002 showed that in a group of 14,000 women in New York City, regular aspirin use (defined as at least once a week, various doses) reduced their risk of lung cancer, especially small-cell carcinoma. This may be because many lung tumors have high amounts of COX-2 enzymes expressed in them, especially in adenocarcinomas and tumors caused by asbestosis. Aspirin is a known blocker of both COX-1 and COX-2 enzymes, although this study suggests that if the COX-2 link is direct, other COX-2 inhibitors may also play a similar role.
Another study in 2002 of both men and women found that risk reduction was more significant in males than females; overall, the effects of smoking were far more influential than aspirin use in determining cancer risks. Of those who smoked, those who smoked the least got the most benefit from aspirin use. Some of the heaviest smokers saw no benefit from aspirin at all.
Aspirin in pets
Aspirin may be used in cats, but only under a veterinarian's strict supervision, as aspirin has a biological half-life of 3 days in cats (cats have trouble breaking down aspirin). Dogs may also use aspirin under a vet's strict supervision, though dogs are more susceptible to aspirin-caused GI bleeds than humans. Aspirin is generally not recommended for pets, though, as there are much safer alternatives for pain relief, and aspirin interacts with several other drugs including cortisones, digoxin, some antibiotics, phenobarbital and furosemide (Lasix).
- DrugBank Aspirin Entry
- An aspirin a day keeps the doctor away
- Colour-enhanced scanning electron micrograph of aspirin crystals
- Aspirin research in the 1990s
- The History of Aspirin
- Aspirin and heart disease
- How Aspirin works
- Molview from bluerhinos.co.uk See Aspirin in 3D
- History of Aspro
- The science behind aspirin
- Ling, Greg (2005). "Aspirin". How Products are Made 1. Thomson Gale.
- Macdonald S (2002). Aspirin use to be banned in under 16 year olds. BMJ 325 (7371): 988.
- Paul B. Hemel and Mary U. Chiltoskey, Cherokee Plants and Their Uses -- A 400 Year History, Sylva, NC: Herald Publishing Co. (1975); cited in Dan Moerman, A Database of Foods, Drugs, Dyes and Fibers of Native American Peoples, Derived from Plants. A search of this database for "salix AND medicine" finds 63 entries.
- Stone, E (1763). An Account of the Success of the Bark of the Willow in the Cure of Agues. Philosophical Transactions 53: 195-200.
- Gerhardt C (1853). Untersuchungen über die wasserfreien organischen Säuren. Annalen der Chemie und Pharmacie 87: 149-179.
- von Gilm H (1859). Acetylderivate der Phloretin- und Salicylsäure. Annalen der Chemie und Pharmacie 112 (2): 180-185.
- Schröder, Prinzhorn, Kraut K (1869). Uber Salicylverbindungen. Annalen der Chemie und Pharmacie 150 (1): 1-20.
- by Charles C. Mann and Mark L. Plummer (1991). The aspirin wars: money, medicine, and 100 years of rampant competition, 25-36, Boston, Mass: Harvard Business School Press.
- Hoffmann H. US Patent 644,077 dated February 27, 1900. US Patent Office. URL accessed on 2007-05-20.
- Aspirin FAQ's. Bayer Healthcare. URL accessed on 2007-05-20.
- Sneader W (2000). The discovery of aspirin: a reappraisal. BMJ 321 (7276): 1591-4.
- Helmstaedter A. Aspirin history: Is there a need for a reappraisal ?. bmj.com Rapid Responses for Sneader, 321 (7276) 1591-1594. URL accessed on 2007-05-20.
- Bayer AG: Zum Vortrag von Dr. Walter Sneader über die Entwicklung der Acetylsalicylsäure. URL accessed on 2007-05-20.
- Acetylsalicylic acid. Jinno Laboratory, School of Materials Science, Toyohashi University of Technology.
- John Robert Vane (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.. Nature - New Biology 231 (25): 232-5.
- "New mechanism of action of Aspirin discovered," in Medical News Today, October 2, 2005.
- ISIS-2 Collaborative group (1988). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.. Lancet (2): 349-60.
- includeonly>Arbor, Ann. "Aspirin may be less effective heart treatment for women than men", University of Michigan, April 26, 2007..
- Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS (24 Apr 2007). Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction. Ann Pharmacother. (May).
- (March 2003) British National Formulary, 45, British Medical Journal and Royal Pharmaceutical Society of Great Britain.
- (2006) British National Formulary for Children, British Medical Journal and Royal Pharmaceutical Society of Great Britain.
- McQuaid KR, Laine L. (2006). Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials.. Am J Med 119 (8): 624-38.
- Gaudreault P, Temple AR, Lovejoy FH Jr. (1982). The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics 70 (4): 566-9.
- Thisted B, Krantz T, Stroom J, Sorensen MB. (1987). Acute salicylate self-poisoning in 177 consecutive patients treated in ICU. Acta Anaesthesiol Scand 31 (4): 312-6.
- Temple AR. (1981). Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 141 (3 Spec No): 364-9.
- Vale JA, Kulig K; American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. (2004). Position paper: gastric lavage.. J Toxicol Clin Toxicol 42 (7): 933-43.
- Hillman RJ, Prescott LF. (1985). Treatment of salicylate poisoning with repeated oral charcoal. Br Med J (Clin Res Ed) 291 (6507): 1472.
- Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. (1990). Does multiple-dose charcoal therapy enhance salicylate excretion?. Arch Intern Med 150 (6): 1281-3.
- Dargan PI, Wallace CI, Jones AL. (2002). An evidenced based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J 19 (3): 206-9.
- Meredith TJ, Vale JA. (1986). Non-narcotic analgesics. Problems of overdosage. Drugs 32 (Suppl 4): 117-205.
- Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Omslaer JC, Drab A, Benson BE (2001). 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 19 (5): 337-95.
- Bosetti, et al. (2006). Aspirin and the risk of prostate cancer. Eur J Cancer Prev 15 (1): 43-5.
- Menezes, et al. (2006). Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 17 (3): 251-6.
- Chan, et al. (2005). Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer. JAMA 294 (8): 914-23.
- Chan, et al. (2004). A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma. Ann Intern Med 140 (3): 157-66.
- Baron, et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (10): 891-9.
- Schernhammer, et al. (2004). A Prospective Study of Aspirin Use and the Risk of Pancreatic Cancer in Women. J Natl Cancer Inst 96 (1): 22-28.
- Bosetti, et al. (2003). Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 88 (5): 672-74.
- Akhmedkhanov, et al. (2002). Aspirin and lung cancer in women. Br J cancer 87 (11): 1337-8.
- Wolff, et al. (1998). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Research 58 (22): 4997-5001.
- Moysich, et al. (2002). Regular aspirin use and lung cancer risk 2 (31).
- Crosby, Janet Tobiassen Veterinary Questions and Answers. About.com.
Analgesics (N02A, N02B)
Buprenorphine, Butorphanol, Codeine, Dextropropoxyphene, Diamorphine, Dihydrocodeine, Fentanyl, Hydrocodone, Hydromorphone, Ketobemidone, Levorphanol, Methadone, Morphine, Nicomorphine, Opium, Oxycodone, Oxymorphone, Pethidine, Tramadol, Tapentadol
|Salicylic acid and derivatives|
Aminophenazone, Metamizole, Phenazone
Paracetamol (acetaminophen), Phenacetin
Non-steroidal anti-inflammatory drugs (primarily M01A and M02A, also N02BA)
Aspirin (Acetylsalicylic Acid), Diflunisal, Ethenzamide, Salicin
Diclofenac, Etodolac, Indometacin, Nabumetone, Sulindac
|2-Arylpropionic acids (profens)|
|N-Arylanthranilic acids (fenamic acids)||
|Topically used products|
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|